Geerts William
Thromboembolism Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):306-11. doi: 10.1182/asheducation-2014.1.306. Epub 2014 Nov 18.
Thrombotic complications associated with the use of central venous catheters (CVCs) are common and lead to distressing patient symptoms, catheter dysfunction, increased risk of infections, long-term central venous stenosis, and considerable costs of care. Risk factors for catheter-related thrombosis include use of larger, multilumen, and peripherally inserted catheters in patients with cancer receiving chemotherapy. Symptomatic catheter-related thrombosis is treated with anticoagulation, generally without removing the catheter. The intensity and duration of anticoagulation depend on the extent of thrombosis, risk of bleeding, and need for continued use of a CVC. To date, the clinical benefit of prophylactic doses of anticoagulant has been disappointing and these agents are not used routinely for this purpose. This chapter focuses on recent evidence, remaining controversies, and practical approaches to reducing the burden of thrombosis associated with CVCs.
与中心静脉导管(CVC)使用相关的血栓形成并发症很常见,会导致患者出现痛苦症状、导管功能障碍、感染风险增加、长期中心静脉狭窄以及高昂的护理成本。导管相关血栓形成的风险因素包括在接受化疗的癌症患者中使用更大、多腔和外周插入的导管。有症状的导管相关血栓形成采用抗凝治疗,一般不拔除导管。抗凝的强度和持续时间取决于血栓形成的程度、出血风险以及继续使用CVC的必要性。迄今为止,预防性剂量抗凝剂的临床获益令人失望,这些药物未常规用于此目的。本章重点关注近期证据、尚存的争议以及减轻与CVC相关血栓形成负担的实用方法。